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Abstract
Introduction: To determine whether single nucleotide polymorphisms (SNPs) in FAS and related genes are
associated with acute kidney injury (AKI) in patients with acute respiratory distress syndrome (ARDS).
Methods: We studied 401 (Caucasian N = 310 and African-American N = 91) patients aged ≥ 13 years with ALI who
enrolled in the Fluid and Catheter Treatment Trial (FACTT) between 2000 and 2005 from 20 North American
centers. We genotyped 367 SNPs in 45 genes of the Fas/Fas ligand pathway to identify associations between SNPs
in Fas pathway genes and the development of AKI by day 2 after enrollment in FACTT, adapting Acute Kidney
Injury Network (AKIN) criteria. Written informed consent was obtained from participants or legally authorized
surrogates in the original FACTT study and available to use for secondary analysis.
Results: In Caucasian patients, we identified associations between two SNPs and the incidence of AKI (stage 1 and
above): rs1050851 and rs2233417; both are found within the gene for nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha (NFKBIA). For rs1050851 and rs2233417, the odds ratios (ORs) were 2.34
(95 % confidence interval (CI) = 1.58–3.46, p = 1.06 × 10−5, FDR = 0.003) and 2.46 (CI = 1.61–3.76, p = 1.81 × 10−5,
FDR = 0.003) for each minor allele, respectively. The associations were stronger still for AKIN stage 2–3 with
respective ORs 4.00 (CI = 2.10–7.62, p = 1.05 × 10−5, FDR = 0.003) and 4.03 (CI = 2.09–7.77, p = 1.88 × 10−5,
FDR = 0.003) for each minor allele homozygote. We observed no significant association between these SNPs and
AKI in the smaller subset of African Americans.
Conclusion: In Caucasian patients with ALI, the presence of minor alleles in two SNPs in NFKBIA was strongly
associated with the development of AKI.
Trial registration: NCT00281268. Registered 20/01/2006.
Introduction
Acute kidney injury (AKI) independently predicts in-
creased in-hospital and long-term mortality [1]. The in-
cidence of severe AKI requiring dialysis has increased
approximately 10 % per year in the USA between 2000
and 2009 [2], and the mainstay of AKI treatment is still
limited to supportive care with or without dialysis [3].
Worldwide, severe AKI is present in approximately 6 %
of critically ill patients admitted to intensive care units,
predominantly in patients with septic shock (in approxi-
mately 48 %), where AKI is associated with mortality of
60 % [4].
A propensity towards inflammation and programmed
cell death or apoptosis of tubular cells may be important
to the pathophysiology of AKI [5–7]. Fas is a trans-
membrane protein in the tumor necrosis factor (TNF)
family that, upon binding Fas ligand (FasL), can induce in-
flammation and apoptosis [8]. FAS gene is constitutively
expressed by renal tubular epithelial cells at baseline, in
balance with cell survival signals [9, 10], and is upregulated
in both acute and chronic kidney disease, leading to apop-
tosis and inflammation [9, 11, 12]. Animal data suggest
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that Fas is a key mediator of apoptosis and inflammation in
AKI [11, 12]. In mice with a loss of function mutation in
FasL (referred to as the gld mutation), Ko et al. observed
less AKI after bilateral renal ischemia reperfusion injury
(IRI) compared to wild-type mice [13]. They also demon-
strated that gld mice had fewer TNF-α producing lympho-
cytes in the kidneys and renal lymph nodes, and that
pharmacologic blockade of FasL prevented AKI in wild-
type mice after IRI. In patients with acute lung injury (ALI)
levels of circulating FasL are associated with changes in
serum creatinine [14]. These findings implicate the Fas
pathway in the pathophysiology of AKI and as a potential
therapeutic target in AKI.
We have previously reported that variants in FAS are
associated with ALI [15]. Mounting data suggest that
there is crosstalk between the kidneys and lungs, and
that AKI and ALI are closely interconnected [14, 16–19].
In this study, we hypothesized that variation in genes in-
volved in inflammation and apoptosis from the FAS path-
way might be associated with development of AKI in
patients with ALI. Using data obtained in the Fluid and
Catheter Treatment Trial (FACTT), a randomized con-
trolled trial in critically ill patients with ALI [20, 21], we
investigated whether genetic variation in single nucleotide




FACTT was a 2 × 2 factorial randomized trial, conducted
by the National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome (ARDS) Clinical
Trials Network. FACTT included 1,000 patients with ALI
for <48 h, randomized to receive conservative vs. liberal
fluid management in one arm, and pulmonary artery cath-
eter (PAC) vs. central venous catheter (CVC) in the other
arm; eligibility and exclusion criteria have been previously
described [20, 21]. To be eligible for enrollment in FACTT,
patients were required to be intubated and on positive-
pressure ventilation, have a ratio of the partial pressure of
arterial oxygen (PaO2) to the fraction of inspired oxygen
(FiO2) <300, and have bilateral infiltrates on chest radiog-
raphy consistent with pulmonary edema without evidence
of left atrial hypertension for <48 h. An additional enroll-
ment requirement was the intent by the primary physician
to insert a CVC. Written informed consent was obtained
from participants or legally authorized surrogates in
the original FACTT study and available to use for
secondary analysis. Further details about the consent
process can be found in the FACTT study [21]. There
was no difference in the incidence of AKI or in re-
ceipt of dialysis between the FACTT treatment arms,
although these were secondary outcomes of the original
studies [21, 22].
Genotyping
Among the 1,000 FACTT patients, 310 Caucasians and
91 African-Americans provided consent for genetic test-
ing. The University of Washington Institutional Review
Board approved this ancillary study. We previously
showed that the baseline characteristics of genotyped vs.
non-genotyped patients in FACTT are very similar [15].
A priori, we performed our analyses separately by race,
to avoid confounding by race. We genotyped 367 SNPs
in 45 genes (Additional file 1: Table S1), chosen from an
annotated pathway diagram of genes involved in the Fas/
FasL pathway [8, 23]. We used re-sequencing informa-
tion available through the NHLBI Program in Genomic
Applications [24], the National Institute of Environmental
Health Sciences Environmental Genome Project [25], and
the International HapMap Project (Release #19) [26] to
calculate linkage disequilibrium (LD) bins (excluding
SNPs with minor allele frequency (MAF) <0.05 and r2 <
0.8) for each of the 45 genes chosen, using LD SELECT
on the genome variation server [27–30]. We then selected
the final 367 TagSNPs from within the identified LD bins
by prioritizing those previously reported to be associated
with a disease or quantitative trait and those more likely
to have functional significance (non-synonymous > syn-
onymous > untranslated region). The selected TagSNPs
covered over 95 % of the common LD bins within the can-
didate genes. The SNPs and their associated genes are listed
in the Additional file 1: Table S2. We used a commercially
available Illumina GoldenGate BeadXpress (San Diego,
USA) system to genotype the selected SNPs [28, 29].
Quality control
Resulting genotype information underwent quality control
at the SNP and subject level. We excluded six patients for
whom <80 % of the SNPs were successfully genotyped
(mean individual call rate 98.5 %) and we excluded 23
SNPs for which <80 % of patients were successfully geno-
typed (mean SNP call rate 93.7 %). After stratifying the
genotyped patients by self-identified race (Caucasian or
African-American), we excluded an additional 30 and 51
SNPs in Caucasians and African-Americans, respectively,
for which the MAF was <0.05. We excluded an additional
30 SNPs in Caucasians and 13 in African-Americans, re-
spectively, for which p values among controls for Fisher’s
exact Hardy Weinberg equilibrium were <1 × 10−3 [31].
After these quality control measures, 284 (77.4 %) and 280
(76.3 %) SNPs remained from 307 Caucasian subjects and
88 African-American subjects, respectively. A flow dia-
gram of patient groups is provided in Fig. 1.
Outcome
Our definition of AKI was adapted from the AKI Network
(AKIN) definition [32, 33]. While the AKIN definition uti-
lizes a sequential, incremental increase in serum creatinine
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(SCr) within 48 h, we used peak compared to trough SCr
within the first 2 days following study enrollment. In doing
so, we aimed to increase the sensitivity for ALI-associated
AKI, which may have occurred before enrollment in
FACTT, as patients could have enrolled up to 48 h after
the onset of ALI. Stage 1 and higher AKI was defined as
an increase in SCr > =0.3 mg/dl or > =50 %. Hourly urine
output was not available in the FACTT database.
Primary analysis
In our primary analysis, we assessed the risk of AKI by
genotypes using logistic regression, assuming an additive
genetic effects model, i.e., each additional copy of the
minor allele (0, 1 or 2) is associated with an incremental
change in risk of AKI. We performed the analysis separ-
ately for each race (Caucasian and African-American). A
priori, we decided to adjust for gender, age, and FACTT
treatment arm. We did not adjust for sepsis because we
were concerned it may sit within the causal pathway
between genotype and AKI. We corrected for multiple
comparisons by using a false discovery rate (FDR) thresh-
old <0.1, which estimates that less than 10 % of the associ-
ations with an FDR value at or below this level are false
positives (29). This is intermediate between using a
raw p value (least conservative) and Bonferroni correction
(most conservative), and accounts for the fact that many
of the genotypes are in partial LD and, thus, many of the
hypothesis tests are correlated. We used Fisher’s exact test
to evaluate genotype frequencies for Hardy-Weinberg
equilibrium. Stata 11.2 and Golden Helix SNP & Variation
Suite 7 were used for the statistical analyses. Assuming an
MAF of 20 % on average, we estimated a power of
80 % to detect an odds ratio (OR) of 1.65 or greater in
the Caucasian patients in our study.
Sensitivity analysis
In sensitivity analysis, we compared the genotypes in those
without AKI to those with severe AKI (modified AKIN
stage 2 and 3). In this analysis, patients subcategorized as
having severe AKI had an increase in SCr >100 %, or had
a rise in SCr to 4.0 mg/dl and an increase of at least
0.5 mg/dl. Patients with stage-1 AKI were excluded from
the sensitivity analysis, thus excluding patients who may
have been misclassified as having AKI with a minimal
increase in SCr [34]. Similar to the primary analysis, we
assessed the risk of AKI by genotypes using logistic
regression with an additive model, and stratified by
race. Clinical outcomes including receipt of dialysis,
mortality, ventilator-free days, and ICU-free days are out-
lined by AKI stage in Additional file 1: Tables S3a and b.
Fig. 1 Flow chart of patient allocation during the study. SNP single nucleotide polymorphism, FasL Fas ligand, AKIN Acute Kidney Injury Network
Bhatraju et al. Critical Care  (2015) 19:368 Page 3 of 9
Results
Baseline characteristics for patients in FACTT included
in this study are outlined in Table 1 (Caucasians) and
Additional file 1: Table S4 (African-Americans). Among
the 307 Caucasian patients from FACTT whom we geno-
typed, 176 (57.3 %) did not develop AKI (AKIN stage 0),
while 99 (32.3 %) developed mild AKI (AKIN stage 1), and
32 (10.4 %) developed moderate to severe AKI (AKIN
stage 2 or 3) within the first 2 days of study enrollment
(Table 1). Among 88 African-Americans, 34 (38.6 %) did
not develop AKI, while 40 (45.5 %) developed mild, and
14 (15.9 %) developed moderate to severe AKI stage dur-
ing the same time period (Additional file 1: Table S4).
Primary analysis
The association tests from the primary analysis are graph-
ically depicted in a quantile-quantile (Q-Q) plot in Fig. 2
for Caucasians and Additional file 2: Figure S1 for African-
Americans. The results from association tests for all the
SNPs tested are outlined in Additional file 1: Tables S5 and
S6 for Caucasians and African-Americans, respectively.
In Caucasians, we observed 22 nominal (p <0.05) associ-
ations with AKI (Table 2) and two of these associations
remained significant after adjustment for multiple hy-
pothesis testing (FDR <0.1): rs1050851 and rs2233417
(Tables 2 and 3). Both of these SNPs are found in
NFKBIA; rs1050851 is a synonymous coding SNP in
exon 2 and rs2233417 is located within intron 4 (based on
dbSNP) [35]. For each of these SNPs, the minor allele was
associated with increased risk for AKI. For rs1050851, each
copy of the A allele was associated with greater than two-
fold increase in risk for AKI (OR 2.34, 95 % CI = 1.58–3.46,
p = 1.06 × 10−5, and FDR = 3.00 × 10−3). For rs2233417,
each copy of the A allele was associated with greater than
two-fold increase in the risk for AKI (OR 2.46, CI = 1.61–
3.76, p = 1.81 × 10−5, and FDR = 2.57 × 10−3).
In African-American patients, we observed 13 nominal
(p <0.05) associations with AKI, however none remained
Table 1 Baseline characteristics of Caucasians in FACTT with genotype data (n = 307)
Characteristic No AKIa Stage 1 AKIa Stage 2 or 3 AKIa
n = 176 (57.3 %) n = 99 (32.3 %) n = 32 (10.4 %)
Age, mean years +/− SD 50.4 +/− 14.6 49.9 +/− 16.3 48.8 +/− 16.1
Male gender 48.9 % 52.5 % 62.5 %
Primary ALI risk factor, n (%)
Aspiration 30 (17.1 %) 20 (20.2 %) 2 (6.3 %)
Multiple transfusions 2 (1.1 %) 2 (2.0 %) 0
Pneumonia 81 (46.0 %) 46 (46.5 %) 11 (34.4 %)
Sepsis 30 (17.1 %) 21 (21.2 %) 17 (53.1 %)
Trauma 17 (9.7 %) 6 (6.1 %) 1 (3.1 %)
Other 16 (9.1 %) 4 (4.0 %) 1 (3.1 %)
APACHE III score, mean +/− SDb 84.4 +/− 25.2 98.8 +/− 30.4 117.4 +/− 26.3
Randomization arm, n (%)
PAC/fluid liberal 47 (26.7 %) 30 (30.3 %) 11 (34.4 %)
PAC/Fluid 43 (24.4 %) 17 (17.2 %) 11 (34.4 %)
Conservative CVC/fluid 39 (22.2 %) 26 (26.3 %) 8 (25.0 %)
Liberal CVC/fluid 47 (26.7 %) 26 (26.3 %) 2 (6.3 %)
Vasopressor usec 55 (31.3 %) 35 (35.4 %) 19 (59.4 %)
Patient location 86 (48.9 %) 58 (58.6 %) 19 (59.4 %)
MICU SICU 21 (11.9 %) 9 (9.1 %) 0
MICU/SICU 41 (23.3 %) 23 (23.2 %) 4 (12.5 %)
Trauma 16 (9.1 %) 6 (6.1 %) 6 (18.8 %)
Other 12 (6.8 %) 3 (3.0 %)
Baseline creatinined, mg/dl (SD) 0.9 (0.4) 1.4 (0.6) 2.1 (1.2)
aAcute kidney injury (AKI) study definitions: no AKI = <0.3 mg/dl and <50 % increase in serum creatinine (SCr); stage 1 AKI = > =0.3 mg/dl and > = 50 % increase in
SCr; stage 2 or 3 AKI = >100 % increase in SCr. bMissing acute physiology and chronic health evaluation (APACHE) score for 9 patients, 5 five patients, and patients
with no AKI, stage 1 and 2 or 3 AKI, respectively. cVasopressor use in the 24 h before Fluid and Catheter Treatment Trial (FACTT) enrollment. dBaseline creatinine
based on average SCr in the 24 h before enrollment in FACTT. ALI acute lung injury, PAC pulmonary artery catheter, CVC central venous catheter, MICU medical
intensive care unit, SICU surgical intensive care unit
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Fig. 2 Observed versus expected associations between Fas pathway single nucleotide polymorphisms (SNPs) and risk of acute kidney injury (AKI)
(stage 1+ vs. stage 0) in the Fluid and Catheter Treatment Trial (FACTT) for Caucasians
Table 2 Fas/Fas ligand pathway polymorphisms associated (p <0.05) with acute kidney injury (AKI) susceptibility in Caucasian
subjects from the Fluid and Catheter Treatment Trial
Gene SNP OR (95 % CI)a P value FDR-adjusted P value MAF
NFKBIA rs1050851 2.34 (1.58–3.46) 1.06 × 10−5 <0.003 0.18
NFKBIA rs2233417 2.46 (1.61–3.76) 1.81 × 10−5 <0.003 0.15
CFLAR rs12105811 0.51 (0.33–0.79) 0.002 0.18 0.25
NFKBIA rs7157810 1.70 (1.15–2.51) 0.007 0.50 0.18
FASLG rs5030772 1.80 (1.16–2.79) 0.007 0.41 0.11
BCL2L1 rs1484994 0.63 (0.44–0.91) 0.011 0.54 0.35
BCL2L1 rs6060621 0.65 (0.45–0.92) 0.015 0.60 0.35
TIRAP rs1786697 0.60 (0.39–0.92) 0.017 0.60 0.23
RELA rs10896027 1.49 (1.06–2.11) 0.022 0.69 0.34
MAP3K1 rs33330 0.64 (0.43–0.95) 0.024 0.69 0.34
NFKBIA rs8904 0.67 (0.47–0.96) 0.027 0.69 0.41
CFLAR rs4482462 0.65 (0.44–0.96) 0.028 0.67 0.27
NFKBIA rs696 0.68 (0.48–0.96) 0.029 0.63 0.41
DAXX rs2239839 1.50 (1.03–2.18) 0.032 0.65 0.26
CFLAR rs6728771 0.66 (0.45–0.97) 0.034 0.64 0.27
MAP3K5 rs911179 0.70 (0.50–0.98) 0.037 0.66 0.48
CASP9 rs1862710 0.71 (0.51–0.99) 0.041 0.68 0.49
MYD88 rs6853 0.61 (0.38–1.00) 0.047 0.76 0.16
BCL2L1 rs6058381 0.53 (0.28–1.02) 0.048 0.72 0.09
TLR6 rs3821985 0.71 (0.50–1.00) 0.049 0.70 0.38
CFLAR rs7583529 0.68 (0.46–1.00) 0.0497 0.67 0.26
MAP3K5 rs1570054 0.71 (0.50–1.00) 0.0498 0.64 0.40
aRisk of AKI (stage 1 or above) with each additional copy of the minor allele. SNP single nucleotide polymorphism, OR odds ratio, FDR false discovery rate, MAF
minor allele frequency
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significant after adjustment for multiple hypothesis test-
ing (Additional file 1: Tables S6a and S7). There were no
significant associations observed between rs1050851 (OR
1.92, CI = 0.51–7.27, p = 0.87, FDR = 0.93) or rs2233417
(OR 0.90, CI = 0.23–3.52, p = 1.00, FDR = 1.00) and AKI.
Given that there were only 88 African-Americans available
for genotyping, our study did not have adequate power to
exclude the presence of an association (Additional file 1:
Table S6a). We also tested recessive genetic models for
associations between these two SNPs and AKI and there
were no statistically significant results in either population.
Thus, we used an additive genetic model for the remain-
der of the analyses.
Sensitivity analysis
The associations for rs1050851 and rs2233417 with AKI
were stronger when we limited the analyses to patients
with moderate to severe AKI or no AKI (OR 4.00, CI =
2.10–7.62, p = 2.78 × 10−5, and FDR = 2.97 × 10−3 for
rs1050851 and OR 4.03, CI = 2.09–7.77, p = 4.68 × 10−5,
and FDR = 2.66 × 10−3 for rs2233417). We observed no
association between rs1050851 (OR 3.76, CI = 0.79–17.77,
p = 0.39, and FDR = 1.00) or rs2233417 (OR 1.13, CI =
0.18–7.32, p = 0.82, FDR = 1.00) and risk of moderate-se-
vere AKI in African-Americans. Using an FDR thresh-
old <0.1, no other associations were significant in our
sensitivity analysis in either Caucasians (Tables 2 and 4) or
African-Americans (Additional file 1: Tables S7a and b) al-
though we did observe nominal (p <0.05) associations
with 15 SNPs and 10 SNPs in Caucasians and African-
Americans, respectively (Table 4 and Additional file 1:
Table S6b, respectively).
Discussion
We now report the first evidence that genetic variation
in NFKBIA is associated with susceptibility to AKI, dis-
covered in this genetic association study examining the
risk of AKI related to Fas and related genes. Fas ligation
leads to a series of intracellular signaling events, culminat-
ing in activation of the death-inducing signaling com-
plexes (DISCs), which promote the activation of caspase-
8-mediated apoptosis. Notably, there are several important
negative regulators of Fas-induced apoptosis including B-
cell lymphoma-2 (BCL2), FLICE-like inhibitory protein
(FLIP), and baculoviral IAP repeat-containing protein 2
(IAP1), all three of which demonstrate NF-kB-dependent
transcription [36, 37]. NFKBIA codes for the cytoplasmic
protein, I-Kappa-B-Alpha (IKBA), that inhibits NF-κB-
mediated transcriptional responses by binding to NF-κB
and retaining it in the cytoplasm [38].
Genetic variation in the promoter region in NFKBIA is
associated with differential susceptibility to pediatric
lung disease [39]. NF-κB is a transcription factor that
regulates activation of the immune and inflammatory re-
sponses [38], has been shown to regulate the expression
Table 3 Genotype counts for rs1050851 and rs2233417 by acute kidney injury (AKI) stage in Caucasian subjects from the Fluid and
Catheter Treatment Trial
AKIN Stage rs1050851 Genotype counts (% per AKI stage) (n = 305a) rs2233417 Genotype counts (% per AKI stage) (n = 305b)
AA AG GG Total AA AG GG Total
0 5 (2.9 %) 53 (30.5 %) 116 (66.7 %) 174 3 (1.7 %) 45 (25.7 %) 127 (72.6 %) 175
1 9 (9.1 %) 42 (42.4 %) 48 (48.5 %) 99 4 (4.1 %) 41 (41.8 %) 53 (54.1 %) 98
2–3 6 (18.8 %) 17 (53.1 %) 9 (28.1 %) 32 5 (15.6 %) 15 (46.9 %) 12 (37.5 %) 32
Total 20 112 173 305 12 101 192 305
aTwo patients had missing genotype for rs1050851; neither had AKI. bTwo patients had missing genotype for rs2233417; one had stage-1 AKI and the other did
not have AKI (stage 0). AKIN Acute Kidney Injury Network
Table 4 Top 15 Fas/Fas ligand pathway polymorphisms in the
Fluid and Catheter Treatment Trial associated with acute kidney
injury (AKI) (stage 2–3 vs. stage 0) in Caucasians (stage 1 excluded)
Gene SNP OR (95 % CI)a P value FDR MAF
NFKBIA rs1050851 4.00(2.10–7.62) 1.05 × 10−5 <0.003 0.18
NFKBIA rs2233417 4.03(2.09–7.77) 1.88 × 10−5 <0.003 0.15
BAX rs4645878 0.12 (0.02–0.90) 0.004 0.41 0.12
TIRAP rs3802814 2.45 (1.28–4.72) 0.008 0.55 0.14
BCL2L1 rs6058381 0.13 (0.02–1.02) 0.008 0.48 0.09
BAXb rs2387583 0.20 (0.05–0.89) 0.009 0.42 0.13
NFKBIA rs7157810 2.19 (1.22–3.94) 0.009 0.38 0.18
BAX rs1010103 0.21 (0.05–0.92) 0.01 0.38 0.13
LY96 rs16938758 2.22 (1.21–4.09) 0.01 0.34 0.17
ALS2CR1 rs17468277 2.36 (1.15–4.88) 0.02 0.67 0.10
DAXX rs2239839 2.05 (1.10–3.82) 0.02 0.61 0.26
CASP8 rs1045485 2.32 (1.12–4.78) 0.03 0.64 0.11
CASP9 rs1820204 1.84 (1.04–3.27) 0.03 0.770 0.47
BCL2 rs1542578 0.55 (0.31–0.97) 0.04 0.72 0.49
TIRAP rs8177343 1.98 (1.03–3.79) 0.04 0.79 0.16
aRisk of AKI (stage 1 or above) with each additional copy of the minor allele.
bAlso nominally associated with stage 2–3 AKI in African-Americans (p <0.05).
SNP single nucleotide polymorphism, OR odds ratio, FDR false discovery rate,
MAF minor allele frequency
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of FasL [40], and is believed to be a mediator of renal
injury in obstructive AKI, [41] and it participates in the
renal development pathway [42]. Taken together, these
findings suggest that NFKBIA might play an important
pathophysiologic role in AKI [38, 40–44].
Our study adds to mounting evidence supporting a
role for genetic variation in modulating risk of AKI.
Prior work has identified associations between genetic
variation in inflammatory pathways and AKI [45]. For
example, Jaber et al. found SNPs in the promoter region
of TNFA and IL10 were associated with decreased risk
of death in patients with AKI, who required dialysis [46].
An SNP in the IL6 has been associated with AKI al-
though follow up studies have not been able to replicate
this association [47–49]. Our study focused on genes
implicated directly or indirectly with the Fas/FasL and
apoptotic pathways so we did not genotype variation in
these genes.
Polymorphisms in BCL2, rs8094315 and rs12457893,
were recently reported to be associated with decreased
risk of developing AKI in patients with septic shock [5].
Our study included rs8094315 as well as other SNPs in
BCL2 but did not include rs12457893. We did not find
an association between SNPs in BCL2 and susceptibility
to AKI but our study subjects differed significantly from
the prior study. Our study included a heterogeneous
group of patients who were enrolled for an interventional
trial in acute respiratory distress syndrome (ARDS) while
the prior study included patients with septic shock,
some of whom went on to develop ARDS. The differ-
ence in underlying illness leading to ICU admission
and subsequent organ dysfunction may explain the
differences in our findings. No prior studies have ex-
amined variation in NFKBIA in relation to risk for
AKI. Future studies in large critically ill populations with
well-defined AKI and associated clinical risks will be ne-
cessary to clarify the role of genetic variation in determin-
ing risk of AKI.
Our study has several limitations. First, not all patients
in the FACTT consented to genetic testing and so we
only have genotypic data for a subset of the original
1,000 patients, however, FACTT patients who were geno-
typed were no different to those who were not genotyped
[15]. Second, multiple hypothesis testing will increase the
likelihood of type I (false positive) errors. However, we
mitigated this possibility by using an FDR cutoff. Third,
our results in Caucasian subjects may not be generalizable
to all populations. Indeed, while the sample size was very
limited, our findings among African-Americans did not
replicate the associations between AKI risk and NFKBIA.
Future studies will need to focus on much larger popula-
tions of non-Caucasians to address this issue. Fourth, our
definition of AKI differs from prior studies reporting the
incidence of AKI in the FACTT. We used a more inclusive
AKI definition in order to minimize the number of AKI
cases misclassified as controls and maximize statistical
power for our genetic study, and this resulted in a higher
incidence (42 %?) than reported by Liu et al. (30.6 %) [22].
Additional studies in prospectively enrolled subjects with
known pre-hospital renal function will be necessary to
clarify which definition better represents true AKI. Finally,
while NFKBIA is certainly biologically plausible as a po-
tential contributor to AKI pathophysiology, further work
will be needed to clarify whether the variants we report as
associated with AKI risk have any functional effect on
expression or function of NFKBIA.
Our study has significant strengths. There is a strong
biologic rationale for the hypothesis that the Fas path-
way is important in AKI, as outlined above. The high-
quality clinical phenotypes and covariates available
through the FACTT provided us with an exceptional op-
portunity to link genotype data with AKI with maximal
precision. Finally, although our findings will need to
be replicated in independent populations, our study is
the largest to evaluate genetic risks for AKI in critic-
ally ill patients from a mixed medical and surgical ICU
population.
Conclusions
This is the first human study to describe an association
between polymorphisms in NFKBIA and AKI. Genotypes
in two SNPs in NFKBIA were associated with increased
AKI occurrence in Caucasians with ALI: rs1050851 (cod-
ing-synonymous) and rs2233417 (intronic). This study
identifies a potential role for NFKBIA in the pathophysi-
ology of AKI in the critically ill.
Key messages
 This is the first human study to describe
associations between nuclear factor of
kappa light polypeptide gene enhancer in
B-cells inhibitor, alpha (NFKBIA) and acute
kidney injury in patients with acute respiratory
distress syndrome
 Two single nucleotide polymorphisms rs1050851
and rs2233417 are both associated with acute kidney
injury
 The OR for rs1050851 was 2.34 (95 % CI = 1.58–3.46,
p = 1.06 × 10−5, FDR = 0.003) for acute kidney injury
and for rs2233417 it was 2.46 (95 % CI = 1.61–3.76,
p = 1.81 × 10−5, FDR = 0.003) for each minor allele,
respectively
 The associations were stronger still for AKIN stage
2–3 with respective ORs of 4.00 (95 % CI = 2.10–
7.62, p = 1.05 × 10−5, FDR = 0.003) and 4.03 (95 %
CI = 2.09–7.77, p = 1.88 × 10−5, FDR = 0.003) for
each minor allele homozygote
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Additional file 1: Table S1. Genes (n = 45) in the Fas/Fas ligand (FasL)
pathway characterized using tag single nucleotide polymorphisms
(tagSNPs). Table S2. TagSNPs genotyped using Illumina GoldenGate
genotyping assays. Table S3a. Outcomes by acute kidney injury (AKI)
stage in Caucasians. Table S3b. Outcomes by AKI stage in African-
Americans. Table S4. Characteristics of African-Americans in the Fluid and
Catheter Treatment Trial (FACTT) with genotype data (n = 88). Table S5a.
Odds ratios for AKI associated with individual SNPs among Caucasians
(comparing no AKI vs. stage 1–3 AKI). Table S5b. Odds ratios for AKI
associated with individual SNPs among Caucasians (comparing no AKI vs.
stage 2–3 AKI). Table S6a. Odds ratios for AKI associated with individual
SNPs among African-Americans (comparing no AKI vs. stage 1–3 AKI).
Table S6b. Odds ratios for AKI associated with individual SNPs among
African-Americans (comparing no AKI vs. stage 2–3 AKI). Table S7a. Fas/FasL
pathway polymorphisms in the FACTT associated (p <0.05) with AKI
susceptibility in African-American subjects from the FACTT. Table S7b.
Fas/FasL pathway polymorphisms in the FACTT associated (p <0.05) with
AKI (stage 2–3 vs. stage 0) in African-Americans (Stage 1 excluded).
(XML 972 bytes)
Additional file 2: Figure S1. Observed versus expected associations
between Fas pathway single nucleotide polymorphisms (SNPs) and risk of
acute kidney injury (AKI) (stage 1+ vs. stage 0) in African-Americans from
the Fluid and Catheter Treatment Trial (FACTT). (DOC 152 kb)
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